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1364 The Journal of Thoracic and CardBackground: Integrated computed tomography–positron emission tomography imaging
with coregistration of anatomic and functional imaging data may improve the accuracy
of malignant pleural mesothelioma staging. We evaluate the use of integrated computed
tomography–positron emission tomography in patients with malignant pleural mesothe-
lioma who are being considered for extrapleural pneumonectomy.
Methods: Twenty-nine patients with malignant pleural mesothelioma who were judged
to be candidates for extrapleural pneumonectomy after clinical and conventional radio-
logic evaluation underwent whole-body integrated computed tomography–positron
emission tomography and pathologic staging. Two reviewers blinded to the results of
clinical and pathologic staging retrospectively evaluated computed tomography,
positron emission tomography, and coregistered computed tomography–positron emis-
sion tomography images. Staging was performed according to the International Me-
sothelioma Interest Group TNM staging system. Histopathology and/or results of further
radiologic evaluation or follow-up served as the reference standard.
Results: Integrated computed tomography–positron emission tomography provided
additional information in 11 of 29 patients that precluded extrapleural pneumonectomy.
The overall tumor stage was correctly classified in 21 of 29 patients. The tumor stage
was correctly determined in 15 of 24 patients, 6 of whom had T4 (nonresectable)
disease. The node stage was accurately determined in 6 of 17 patients. Extrathoracic
metastases not identified by routine clinical and conventional radiologic evaluation were
detected in 7 of 29 patients and were found to be diffuse (n  2) or solitary (n  5).
Conclusions: Integrated computed tomography–positron emission tomography in-
creases the accuracy of malignant pleural mesothelioma staging and is important in
determining the appropriate therapy in patients being considered for extrapleural
pneumonectomy.
Malignant pleural mesothelioma (MPM) is an uncommon neoplasm arisingfrom mesothelial cells of the pleura with an annual incidence of approx-imately 2500 to 3000 cases in the United States.1,2 Advances in the
management of MPM have occurred during the past few years, including the
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ETadoption of an internationally accepted staging system, new
active chemotherapeutic regimens, novel targeted agents,
improved approaches for local control, and decreased mor-
bidity and mortality in patients who undergo extrapleural
pneumonectomy (EPP).3-8 However, there is not a univer-
sally accepted standard therapy for MPM, and the prognosis
remains poor. Failure of single-modality therapy has re-
sulted in the use of multimodality regimens combining
chemotherapy, radiotherapy, immunotherapy, and surgery,
with an increasing tendency to perform surgical resection in
cases of limited disease.4,5,6,9-11 EPP is the surgical proce-
dure of choice for patients with MPM who present with
resectable disease.5,9 In an attempt to distinguish these
patients from those requiring palliative treatment, the Inter-
national Mesothelioma Interest Group staging system for
MPM, accepted by the American Joint Committee on Can-
cer and the International Union Against Cancer, describes
the anatomic extent of disease according to a traditional
TNM system.3,12 A consequence of the increasing use of
TNM staging is that accurate determination of the anatomic
extent of disease is important in selecting patients for po-
tentially curative resection. Computed tomography (CT) is
usually performed to assess the extent of local chest wall
and mediastinal invasion and presence of nodal and lung
metastases in patients with MPM.13,14 However, CT often
fails to predict resectability. The use of positron emission
tomography (PET) with [18F]-fluoro-2-deoxy-D-glucose
(FDG) in the evaluation of patients with MPM has been
reported.15-20 Most of these studies were small, though, and
the poor spatial resolution of PET when compared with that
of CT often precluded assessment of the presence and extent
of local tumor invasion.
The recent use of integrated CT-PET imaging with
coregistration of anatomic and functional imaging data may
improve the localization of regions of increased FDG up-
take and accuracy of staging in patients with MPM. How-
ever, the role of FDG-PET and integrated CT-PET imaging
in the staging of MPM has not been fully elucidated. There-
fore, in this article, we report on the role of CT-PET
imaging in patients with MPM who are being considered for
EPP.
Methods
Thirty-three patients with biopsy-proven MPM were referred to
The University of Texas M.D. Anderson Cancer Center for pos-
sible enrollment in an institutional review board-approved phase II
study investigating the feasibility of EPP followed by intensity-
modulated radiation therapy. Patients with mesothelioma of all
histologic subtypes were eligible for this study. All patients un-
derwent whole-body integrated CT-PET before surgical staging
consisting of bronchoscopy, mediastinoscopy to exclude contralat-
eral mediastinal nodal metastases, and/or laparoscopy with perito-
neal lavage to rule out abdominal involvement. Four patients were
excluded from the study group because of medical comorbidity.
The Journal of ThoracicThe final study group consisted of 29 patients (26 men and 3
women; mean age 63 years [range, 44-77 years]).
CT-PET Imaging Parameters
An integrated CT-PET scanner (Discovery ST-8; General Electric
Medical Systems, Milwaukee, Wis) was used. PET images were
acquired during shallow breathing in the 2-dimensional mode for
3 minutes per bed position 60 to 90 minutes after intravenous
administration of 555 to 740 MBq of FDG. Non–contrast-
enhanced CT images were acquired in helical mode (speed, 13.5
mm/rotation) from the base of the skull to the mid-thighs during
suspended mid-expiration at a 3.75-mm slice thickness, 140 kVp,
and 120 mA.
CT-PET Imaging Interpretation
Two reviewers experienced in CT and PET interpretation retro-
spectively reviewed the CT-PET scans. Both reviewers were
blinded to the results of mediastinoscopy, laparoscopy, and sur-
gery. The findings were recorded by consensus. The PET and CT
images were reviewed on a Xeleris workstation (General Electric
Medical Systems). CT, PET, and coregistered CT-PET images
were available for review in all standard planes. PET scans were
analyzed visually and quantitatively. FDG uptake was considered
to be abnormal on visual analysis when it was substantially greater
than the mediastinal blood pool activity on the attenuation-cor-
rected images. A pixel region of interest was also outlined within
regions of increased FDG uptake and measured on each slice. The
highest recorded FDG uptake was semiquantitatively analyzed
according to the following formula: maximum standardized uptake
value (SUV)  decay-corrected activity (millicuries/milliliter)/
injected FDG dose (millicuries)/body weight (gram).
Surgical Procedures
All surgical staging procedures and EPPs were performed by
experienced thoracic surgeons. Laparoscopy consisted of direct
visualization of the diaphragm with biopsy analysis of any visible
abnormalities as well as peritoneal lavage. Mediastinoscopy was
used to evaluate the mediastinal nodes, and specimens were clas-
sified according to the American Thoracic Society mapping sys-
tem.21 Because patients with N2 disease were eligible for EPP,
mediastinoscopy was only performed to evaluate for N3 disease
that would have precluded surgery.
Staging Considerations
Disease in the patients was staged according to the International
Mesothelioma Interest Group TNM staging system by combining
the information obtained from the CT and PET scans.12 In our
protocol, patients with stage I to III MPM (T1-3 N1-2 M0) were
eligible for EPP, whereas those with stage IV MPM (any T4, any
N3, any M1) were not. FDG-avid lymph nodes on PET, regardless
of size on CT, were interpreted as positive for metastasis. Because
patients with N2 nodes were eligible for EPP, PET information
was used to direct invasive sampling in patients with FDG-avid N3
nodes. In terms of extrathoracic PET positive foci, if CT showed
anatomic abnormalities suspicious for metastases, patients were
excluded from surgery and underwent palliative therapy. The
decision to obtain pathologic confirmation of metastatic disease
was at the discretion of the treating physician.
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preoperative assessment of patients with MPM, particularly to eval-
uate for diaphragmatic involvement, our institution does not because
of the limitation of this modality in detecting subtle transdiaphrag-
matic invasion. Instead, laparoscopy to directly visualize the under-
surface of the diaphragm and detect small volume disease as well as
peritoneal lavage was performed in our study patients.
Statistical Analysis
Statistical analysis was performed with the SPSS version 11 soft-
ware program (SPSS Inc, Chicago, Ill). The sensitivity, specificity,
positive predictive value, negative predictive value, and accuracy
of CT-PET imaging in TNM staging were determined. The SUV of
the primary tumor on PET was compared with histology using the
1-way analysis of variance.
Results
T Staging
All patients had increased FDG uptake in their primary
TABLE 1. Patient data
Patient
No. Age Sex Histology Tumor SUV Tumor R/L Pro
1 58 M E 8.9 R E
2 61 M M 3.0 R E
3 66 M E 10.0 R E
4 63 M E 11.0 R E
5 62 M E 8.7 R E
6 60 M M 20.0 L E
7 57 M M 6.4 L E
8 64 M M 8.5 R E
9 65 F M 11.4 R E
10 60 M E 8.0 R E
11 77 M S 12.0 R E
12 58 F E 11.2 L E
13 44 M E 7.9 L E
14 51 M E 12.9 R E
15 58 M E 16.0 L E
16 73 M M 11.5 R E
17 58 M E 10.5 R
18 73 M S 9.8 L
19 65 M E 12.0 L L
20 61 M E 5.6 R L
21 60 M E 10.5 R L
22 65 M S 10.5 R L
23 68 M S 16.0 R L
24 64 M E 11.6 R L
25 62 M E 11.8 L
26 70 M E 10.5 L
27 67 F E 4.4 L
28 64 M E 15.0 L
29 66 M S 10.0 R
E, Epithelial; S, sarcomatoid, M, mixed; EPP, extrapleural pneumonectomy;
standardized uptake value; CT-PET, computed tomography–positron emis
follow-up; TNM: X, not confirmed.tumor (mean SUV, 10.5 [range, 3-20]). There was no sta-
1366 The Journal of Thoracic and Cardiovascular Surgery ● Juntistically significant correlation (P  .727) between the
SUV of FDG uptake in the primary tumor and histology:
epithelioid (n  18; mean, 10.4 [range, 4.4-16.0]), sarco-
matoid (n  5; mean SUV, 11.7 [range, 9.8-16.0]), and
mixed (n  6; mean SUV, 10.1 [range, 3.0-20.0]). Evalu-
ation of T staging with CT-PET was based on patients in
whom the T stage was verified histopathologically after EPP
(n 16) or exploratory thoracotomy (n 2) and laparoscopy
(n  24). T stage could not be determined in 5 of the 29
patients because these patients were precluded from surgery
when M1 disease was detected on CT-PET. The T stage was
accurately determined on CT-PET in 15 of the 24 patients
(63%) (T1, n 0; T2, n 2; T3, n 7; T4, n 6) (Table 1).
Of the 6 patients with T4 MPM, 4 had transdiaphragmatic
extension of the tumor into the peritoneum.
CT-PET overstaged T disease in 2 patients (8%). One of
these patients was determined by CT-PET to have T4 dis-
e CT-PET TNM
Reference
standard TNM CT-PET stage
Reference
standard stage
T2 N3 M0 T2 N0 M0 IV II
T2 N0 M0 T2 N0 M0 II II
T1 N1 M0 T2 N0 M0 III II
T3 N0 M0 T2 N1 M0 III III
T1 N0 M0 T2 N2 M0 I III
T3 N0 M0 T3 N0 M0 III III
T3 N0 M0 T3 N0 M0 III III
T2 N3 M0 T3 N1 M0 IV III
T3 N2 M0 T3 N1 M0 III III
T3 N1 M0 T3 N2 M0 III III
T3 N0 M0 T3 N2 M0 III III
T4 N0 M0 T3 N2 M0 IV III
T3 N0 M0 T3 N2 M0 III III
T2 N3 M0 T3 N2 M0 IV III
T3 N2 M0 T3 N2 M0 III III
T4 N2 M0 T4 N2 M0 IV IV
T4 N0 M0 T4 N0 M0 IV IV
T4 N2 M0 T4 NX M0 IV IV
T4 N0 M0 T4 NX M0 IV IV
T2 N0 M0 T4 NX M0 II IV
T2 N2 M0 T4 NX M0 III IV
T4 N0 M0 T4 NX M0 IV IV
T4 N0 M1 T4 NX M1 IV IV
T3 N3 M1 T4 NX M1 IV IV
T3 N2 M1 TX NX M1 IV IV
T3 N3 M1 TX NX M1 IV IV
T2 N1 M1 TX NX M1 IV IV
T3 N2 M1 TX NX M1 IV IV
T4 N0 M1 TX NX M1 IV IV
ploratory thoracotomy; Lap, laparoscopy; Bx, abdominal node biopsy; SUV,
tomography. *No invasive procedure. M1 disease confirmed by imagingcedur
PP
PP
PP
PP
PP
PP
PP
PP
PP
PP
PP
PP
PP
PP
PP
PP
ET
ET
ap
ap
ap
ap
ap
ap
Bx
*
*
*
*
ET, ex
sionease because of transmural pericardial involvement; surgi-
e 2005
Erasmus et al Evolving Technology
ETcal resection revealed nontransmural involvement of the
pericardium (T3 disease). The second patient was deter-
mined to have nontransmural pericardial involvement (T3
disease) that was not confirmed at surgical resection.
CT-PET understaged T disease in 7 patients (29%). In 3
patients CT-PET did not detect transdiaphragmatic tumor
extension into the peritoneum (T4 disease) diagnosed at
laparoscopic evaluation. Peritoneal involvement was diag-
nosed by biopsy analysis of small (5 mm) focal nodules
on the inferior diaphragmatic surface in 2 of these patients
and by peritoneal lavage in 1 patient. The remaining 4
patients had focal chest wall, lung, and/or diaphragmatic
invasion revealed at surgical resection that was not detected
by CT-PET. The sensitivity, specificity, positive predictive
value, negative predictive value, and accuracy of CT-PET
for T4 disease were 67%, 93%, 86%, 82%, and 83%,
respectively.
N Staging
Evaluation of N staging by CT-PET was based on resection
of lymph nodes at EPP (n  16) and exploratory thoracot-
omy (n  1). Correlation of the CT-PET findings with N
staging was only possible in 17 patients who underwent
complete staging by lymph node dissection. The findings of
node evaluation by CT-PET were not compared with those
of mediastinoscopy, because biopsy analysis was only per-
formed to detect contralateral or nonresectable (N3) disease.
The N stage was accurately determined in 6 of the 17
patients (35%: N0, n  4; N1, n  0; N2, n  2; N3, n 
0) (Table 1).
CT-PET overstaged the nodal involvement in 5 patients
(29%). Two patients were determined to have N0 and N1
disease by CT-PET; surgical resection showed N1 and N2
disease, respectively. Three patients were determined to
have contralateral mediastinal and/or supraclavicular nodal
metastases (N3 disease); mediastinoscopy and surgical re-
section revealed N0, N1, and N2 disease in these 3 patients.
CT-PET understaged the nodal involvement in 6 patients
(35%). Five patients were determined to have N0 disease by
CT-PET; surgical resection revealed N1 disease in 1 patient
and N2 disease in 4 patients. The sixth patient was deter-
mined to have N1 disease; surgical resection revealed N2
disease. The sensitivity, specificity, positive predictive
value, negative predictive value, and accuracy of CT-PET in
lymph node staging in patients with N2 disease were 38%,
78%, 60%, 58%, and 59%, respectively.
M Staging
In 7 of the 29 patients (24%), CT-PET detected extratho-
racic metastases that were not suspected after routine clin-
ical and conventional radiologic evaluation (Table 1). His-
topathologic analysis in these patients revealed epithelial (n
 5) and sarcomatoid (n  2) tumors. Two patients had
The Journal of Thoracicdiffuse metastases (lung, bone, adrenal, abdominal nodes,
and/or abdominal wall), and 5 had a solitary metastasis
(bone, n  1; abdominal lymph nodes, n  4). Evaluation
of M staging by CT-PET was based on further radiologic
evaluation or follow-up (n  6) and abdominal lymph node
biopsy analysis (n  1). In the 4 patients with abdominal
nodal metastasis, the lymph nodes (mean diameter, 1.4 cm
[range, 1.0-1.5 cm]; mean SUV, 6.9 [range, 4.5-9.3]) were
located in the region of the celiac axis (n  3) or the
retroperitoneum (n  1).
International Mesothelioma Interest Group Tumor
Staging
CT-PET correctly assigned the overall stage of MPM in 21
of the 29 patients (72%) initially judged to be candidates for
surgical resection after clinical and CT evaluation (stage I,
n  0; stage II, n  1; stage III, n  8; stage IV, n  12).
CT-PET accurately detected stage IV disease in 12 of 14
patients (86%). Of these 12 patients, 5 had a locally ad-
vanced, technically unresectable tumor, 2 had a technically
unresectable tumor and metastatic disease, and 5 had ex-
trathoracic metastases that were not suspected after routine
clinical and conventional radiologic evaluation. One of the
patients deemed as having an unresectable tumor underwent
EPP. This patient had transdiaphragmatic extension of the
tumor into the peritoneum (T4 disease) that was diagnosed
by CT-PET. However, because laparoscopy and peritoneal
lavage were negative for malignant cells, the patient then
underwent surgery. Histopathologic analysis of the resected
tumor revealed transdiaphragmatic extension of the tumor.
CT-PET overstaged the overall stage of MPM in 5 pa-
tients. Four of these patients were incorrectly considered to
have nonresectable disease because of involvement of con-
tralateral mediastinal or supraclavicular nodes (n  3) or
transmural pericardial involvement (n  1). All 5 patients
underwent EPP. Also, CT-PET understaged the overall
stage of MPM in 3 patients. All 3 patients were initially
considered to have potentially resectable disease. However,
2 patients were found to have nonresectable disease after
laparoscopic detection of small (5 mm in diameter) foci of
peritoneal tumor.
Discussion
The results of this study show that integrated CT-PET with
coregistration of anatomic and functional imaging data im-
proves the accuracy of MPM staging and is important in
determining the appropriate therapy in patients being con-
sidered for EPP. Specifically, integrated CT-PET was the
most important component in determining the patients’ el-
igibility for EPP. EPP would have been precluded because
of CT-PET findings in 12 of the 29 patients (41%). Seven of
these 12 patients had extrathoracic metastases detected by
CT-PET that were not identified by routine clinical and
conventional radiologic evaluation (Figures 1 and 2).
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ETSchneider and colleagues18 have also reported the useful-
ness of PET in detecting occult metastases in 2 of 18
patients with MPM who were precluded from surgery by
PET. Others have reported that distant metastasis may be
the initial site of relapse after EPP, and this could reflect
limitations in conventional staging with CT.22 Our findings
suggest that distant MPM metastases that develop soon after
EPP are likely present at the time of surgery but are not
detected by conventional staging. Improvement in the ac-
curacy of M staging with CT-PET may lead to more appro-
priate selection of patients for EPP and decrease the number
of patients with early recurrence of MPM.
The International Mesothelioma Interest Group staging
system for MPM emphasizes the importance of local tumor
invasion in determining resectability.12 However, the qual-
ifications for T staging are postoperative pathologic descrip-1368 The Journal of Thoracic and Cardiovascular Surgery ● Juntors that are often difficult to determine by CT and MR
imaging. In our study, the sensitivity of CT-PET in detect-
ing T4 disease was 67% compared to 19% using PET alone
reported by Flores and colleagues.17 Similar limitations in T
staging were also reported by Schneider and colleagues18
when PET failed to detect chest wall and transdiaphrag-
matic invasion in 2 of 18 patients with MPM. The inaccu-
racy of CT in assessing transdiaphragmatic extension of
MPM is because of its inability to detect microscopic inva-
sion and the inherent limitation of axial imaging to delineate
the diaphragm from primary tumor. In our study, the use of
whole-body CT-PET capable of high-resolution multiplanar
reconstruction allowed for more optimal evaluation of the
diaphragm with sagittal and coronal images (Figure 3).
Diaphragmatic T4 disease was confirmed pathologically in
all 4 patients identified on CT-PET as having transdiaphrag-
Figure 1. Coronal computed tomography (CT) (A),
positron emission tomography (PET) (B), and inte-
grated CT-PET (C) show diffuse uptake of [18F]-
fluoro-2-deoxy-D-glucose (FDG) in primary left pleu-
ral tumor and focal area of increased uptake in the
abdomen (arrow) localized to an abdominal lymph
node. Biopsy confirmed nodal metastasis, preclud-
ing patient from extrapleural pneumonectomy (EPP).
L, Liver.
Figure 2. Coronal CT (A), PET (B), and integrated
CT-PET (C) show diffuse uptake of FDG in primary
left pleural tumor and focal areas of increased up-
take in the pelvis localized to right iliac bone and
left femoral neck. These occult metastases were not
detected on conventional staging evaluation.e 2005
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ETmatic extension. It is important to note that PET alone lacks
the spatial resolution to detect transdiaphragmatic extension
of tumor and in our study would have precluded fewer
patients from EPP than CT-PET.
Two patients with potentially resectable disease were
found to have T4 disease (transdiaphragmatic peritoneal
involvement) by laparoscopy and peritoneal biopsy analy-
sis. Their tumor implants were small (5 mm in diameter)
and would not have been detected by conventional imaging.
Preoperative laparoscopy is not the standard of evaluation
of MPM, because many institutions use magnetic resonance
imaging to evaluate for suspected diaphragmatic invasion.
However, because of the morbidity and mortality associated
with EPP, we recommend laparoscopic evaluation in all
patients considered for EPP.
Recently, researchers have reported better survival in
patients who undergo EPP for epithelial MPM after com-
plete local resection and an absence of nodal metastases.5,22
PET may have a role in the evaluation of nodal metastases,
particularly those not accessible by mediastinoscopy. PET
has been reported to detect nodal MPM metastases in small
studies.15,18,19 A study by Benard and colleagues19 in 1998
reported a sensitivity of 83% of PET for nodal metastases.
However, a more recent study reported a sensitivity of only
11%.17 Our study shows that CT-PET is inaccurate in
evaluating nodal MPM metastases. CT-PET did not detect
the metastases in the 3 patients with pathologic N1 disease
because of the presence of confluent adjacent primary tumor
The Journal of Thoracicor absence of increased FGD-uptake in the hilum. Also,
CT-PET detected the metastases in only 2 of the 8 patients
with N2 disease. Although this may affect prognosis, it did
not affect surgical management. Furthermore, CT-PET in-
accurately staged MPM as N3 (nonresectable) disease in 3
patients. In 2 of these patients, false-positive increased FDG
uptake in the N3 nodes was attributable to inflammation on
histopathologic examination. Because of the implications
for management, we advocate sampling of all FDG-avid N3
nodes in patients with MPM. In addition, N3 lymph nodes
that are enlarged according to CT criteria and are not FDG
avid should be sampled in patients considered for surgery.
In summary, the use of integrated CT-PET in patients
with MPM increases the accuracy of overall staging and
significantly improves the selection of patients for EPP. Our
study suggests that whole-body integrated CT-PET should
be the preferred modality for staging in patients with MPM.
References
1. Price B, Ware A. Mesothelioma trends in the United States: an update
based on surveillance, epidemiology, and end results program data for
1973 through 2003. Am J Epidemiol. 2004;159:107-12.
2. Weill H, Hughes JM, Churg AM. Changing trends in US mesotheli-
oma incidence. Occup Environ Med. 2004;61:438-41.
3. Greene FL, Page DL, Fleming ID, Fritz A, Balch CM, Haller DG, et
al. Pleural mesothelioma: In: Greene F, Page DL, Fleming ID, et al,
editors. American Joint Committee on Cancer (AJCC) cancer staging
manual. 6th ed. New York: Springer-Verlag; 2002. p. 179-84.
Figure 3. Sagittal CT (A), PET (B), and integrated
CT-PET (C) show diffuse uptake of FDG in malignant
pleural mesothelioma (MPM). Multiplanar recon-
struction is useful in evaluating diaphragm and
shows normal diaphragmatic contour (white arrow-
heads) and focal lobular irregularity (black arrow-
heads) suspicious for transdiaphragmatic extension
of tumor. Laparoscopic biopsy confirmed T4 disease.
S, Spleen.4. Khalil MY, Mapa M, Shin HJ, Shin DM. Advances in the management
of malignant mesothelioma. Curr Oncol Rep. 2003;5:334-41.
and Cardiovascular Surgery ● Volume 129, Number 6 1369
Evolving Technology Erasmus et al
ET5. Sugarbaker DJ, Flores RM, Jaklitsch MT, et al. Resection margins,
extrapleural nodal status, and cell type determine postoperative long-
term survival in trimodality therapy of malignant pleural mesotheli-
oma: results in 183 patients. J Thorac Cardiovasc Surg. 1999;117:54-
63; discussion 63-5.
6. Ahamad A, Stevens CW, Smythe WR, et al. Promising early local
control of malignant pleural mesothelioma following postoperative
intensity modulated radiotherapy (IMRT) to the chest. Cancer J.
2003;9:476-84.
7. Nowak AK, Lake RA, Kindler HL, Robinson BW. New approaches
for mesothelioma: biologics, vaccines, gene therapy, and other novel
agents. Semin Oncol. 2002;29:82-96.
8. Vogelzang NJ, Rusthoven JJ, Symanowski J, et al. Phase III study of
pemetrexed in combination with cisplatin versus cisplatin alone in
patients with malignant pleural mesothelioma. J Clin Oncol. 2003;21:
2636-44.
9. Yoshino I, Yamaguchi M, Okamoto T, et al. Multimodal treatment for
resectable epithelial type malignant pleural mesothelioma. World
J Surg Oncol. 2004;2:11.
10. Zellos LS, Sugarbaker DJ. Multimodality treatment of diffuse malig-
nant pleural mesothelioma. Semin Oncol. 2002;29:41-50.
11. Catalano A, Gianni W, Procopio A. Experimental therapy of malignant
mesothelioma: new perspectives from anti-angiogenic treatments. Crit
Rev Oncol Hematol. 2004;50:101-9.
12. Rusch VW. A proposed new international TNM staging system for
malignant pleural mesothelioma. From the International Mesothelioma
Interest Group. Chest. 1995;108:1122-8.
13. Patz EF Jr, Shaffer K, Piwnica-Worms DR, et al. Malignant pleural
mesothelioma: value of CT and MR imaging in predicting resectabil-
ity. AJR Am J Roentgenol. 1992;159:961-6.
1370 The Journal of Thoracic and Cardiovascular Surgery ● Jun14. Heelan RT, Rusch VW, Begg CB, Panicek DM, Caravelli JF, Eisen C.
Staging of malignant pleural mesothelioma: comparison of CT and
MR imaging. AJR Am J Roentgenol. 1999;172:1039-47.
15. Nanni C, Castellucci P, Farsad M, et al. Role of 18f-FDG PET for
evaluating malignant pleural mesothelioma. Cancer Biother Radio-
pharm. 2004;19:149-54.
16. Gerbaudo VH, Sugarbaker DJ, Britz-Cunningham S, Di Carli MF,
Mauceri C, Treves ST. Assessment of malignant pleural mesothelioma
with (18)F-FDG dual-head gamma-camera coincidence imaging: com-
parison with histopathology. J Nucl Med. 2002;43:1144-9.
17. Flores RM, Akhurst T, Gonen M, Larson SM, Rusch VW. Positron
emission tomography defines metastatic disease but not locoregional
disease in patients with malignant pleural mesothelioma. J Thorac
Cardiovasc Surg. 2003;126:11-6.
18. Schneider DB, Clary-Macy C, Challa S, et al. Positron emission
tomography with F18-fluorodeoxyglucose in the staging and preoper-
ative evaluation of malignant pleural mesothelioma. J Thorac Cardio-
vasc Surg. 2000;120:128-33.
19. Benard F, Sterman D, Smith RJ, Kaiser LR, Albelda SM, Alavi A.
Metabolic imaging of malignant pleural mesothelioma with fluorode-
oxyglucose positron emission tomography. Chest. 1998;114:713-22.
20. Zubeldia J, Abou-Zied M, Nabi H. 11. Evaluation of patients with
known mesothelioma with 18F-fluorodeoxyglucose and PET. Com-
parison with computed tomography. Clin Positron Imaging. 2000;3:
165.
21. Mountain CF, Dresler CM. Regional lymph node classification for
lung cancer staging. Chest. 1997;111:1718-23.
22. Rusch VW, Venkatraman E. The importance of surgical staging in the
treatment of malignant pleural mesothelioma. J Thorac Cardiovasc
Surg. 1996;111:815-25; discussion 25-6.
e 2005
